Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

MSCL.TO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Satellos Bioscience Inc.TSX: MSCL.TO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows 33.4% year over year

Q1 FY2026 weighted avg shares of 18.44M shares rose 33.4% year over year. Sequentially, it rose 19.3% from the prior quarter. Over 3 fiscal years it compounded at +70.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
18.44M+19.3% QoQ
Last fiscal yearDec 2025
14.6M+52.6% YoY
LTMMar 2026
15.53M— YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.4%——
1 year+52.6%——
3-year CAGR+70.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
14.6M USD
Year-over-year change
—

Weighted Avg Shares vs competitors

How MSCL.TO compares with its peers on the latest reported figures

  • MSCL.TO's LTM Mar 2026 weighted avg shares of 15.53M shares is the lowest of the 4 companies compared; the peer median is 94.16M shares.
  • Over three fiscal years its annual growth of +70.0% compares with a peer median of +11.6%.
MSCL.TO Competitors Peer median
Weighted Avg Shares for MSCL.TO and competitors
Company Period LTM YoY 3-year CAGR
SVA.TOSernova Corp.LTM Apr 2026337.21M +6.6%+6.3%
CRDL.TOCardiol Therapeutics Inc.LTM Mar 202694.16M +24.3%+11.6%
HBP.TOHelix BioPharma Corp.LTM Apr 202675.7M +289.1%+23.1%
MSCL.TOSatellos Bioscience Inc.LTM Mar 202615.53M —+70.0%
Peer median (excluding MSCL.TO) 94.16M+24.3%+11.6%

Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue165.69K3.73M8.82M20K5.09K
Gross Profit(165.69K)(3.73M)(8.82M)(20K)(5.09K)
Gross Margin—————
Research & Development1.88M2.59M8.82M19.6M18.75M
Selling, General & Admin2.8M5.49M6.64M8.19M7.44M
Operating Expenses4.7M4.69M15.46M27.79M26.92M
Depreciation & Amortization165.69K337K7K20K5.09K
EBITDA(4.6M)(8.09M)(15.71M)(28.08M)(26.92M)
EBITDA Margin—————
Operating Income(6.65M)(8.43M)(15.46M)(27.81M)(26.92M)
Operating Margin—————
Interest Income7.99K63K1.33M1.37M1.38M
Interest Expense985.33K0177K00
Other Income / Expenses(8.86M)(2.89M)(426K)(291K)1.79M
Income Before Tax(15.51M)(11.32M)(15.89M)(28.1M)(25.13M)
Pre-Tax Margin—————
Income Tax Expense(42.41K)5K00175.01K
Net Income(15.51M)(11.32M)(15.89M)(28.1M)(25.31M)
Net Margin—————
EPS (Basic)(7.73)(3.81)(2.21)(2.94)(1.73)
EPS (Diluted)(7.73)(3.81)(2.21)(2.94)(1.73)
Weighted Avg Shares2.01M2.97M7.2M9.56M14.6M
Weighted Avg Shares (Diluted)2.01M2.97M7.2M9.56M14.6M

Satellos Bioscience Inc.

TSX:MSCL.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.